Humulina Regular

Humulina Regular is a recombinant human insulin (Insulin human, rDNA) supplied as a 100 units/mL injectable solution for subcutaneous, intramuscular, or intravenous administration. It is a prescription‑only antidiabetic agent marketed in the European Union. The product is used to replace or supplement endogenous insulin in patients with diabetes mellitus and is also employed in acute care settings such as diabetic ketoacidosis under medical supervision and individualized dosing.

Humulina Regular is indicated for several clinical situations where insulin replacement is required.

- Management of type 1 diabetes mellitus - Management of type 2 diabetes mellitus - Intravenous treatment of diabetic ketoacidosis - Use in gestational diabetes when other options are unsuitable - Perioperative glucose control in surgical patients - Control of hyperglycemia in critically ill patients

Like all insulin preparations, Humulina Regular may be associated with adverse reactions that vary in frequency and severity.

Common: - Hypoglycemia (low blood glucose) - Injection‑site pain, erythema, or lipohypertrophy - Weight gain - Peripheral edema

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures - Allergic reactions including anaphylaxis or urticaria - Hypokalemia (low potassium levels) - Development of insulin antibodies that may alter insulin action

Clinicians should consider several precautionary measures when prescribing Humulina Regular to ensure safe and effective use.

- Assess renal and hepatic function before initiation and adjust therapy as needed - Use lower initial doses in elderly or frail patients - Monitor blood glucose closely during illness, stress, or changes in diet - Counsel patients on proper injection technique to avoid lipohypertrophy - Avoid use in individuals with known hypersensitivity to human insulin - Review pregnancy status; although category B, insulin therapy requires medical supervision - Educate patients on recognizing and managing hypoglycemia

Humulina Regular can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Sulfonylureas or meglitinides (increased risk of hypoglycemia) - Beta‑blockers (may mask hypoglycemia symptoms) - MAO‑A inhibitors (potentiated hypoglycemia) - High‑dose corticosteroids (counteract insulin effect)

Use with caution: - ACE inhibitors or ARBs (may enhance insulin sensitivity) - Thiazide diuretics (may raise blood glucose) - Alcohol (unpredictable glucose changes) - Certain antidepressants such as SSRIs (potential glucose variability) - Concomitant use of other antidiabetic agents (requires dose adjustments)